We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vnus Medical Technologies (MM) | NASDAQ:VNUS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 29.00 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE TO
(Amendment No. 2)
TENDER OFFER STATEMENT
UNDER SECTION 14(D)(1) OR SECTION 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934
VNUS MEDICAL TECHNOLOGIES, INC.
(Name Of Subject Company (Issuer))
COVIDIEN GROUP S.A.R.L.
COVIDIEN DELAWARE CORP.
(Names of Filing Persons (Offerors))
Common Stock, par value $0.001 per share
(Title of Class of Securities)
928566108
(CUSIP Number of Common Stock)
Michelangelo Stefani
Covidien Group S.a.r.l.
3b Bld Prince Henri
L-1724, Luxembourg
Telephone: +352 266 379 31
(Name, address and telephone number of person authorized
to receive notices and communications on behalf of filing persons)
with copies to:
Paul Kinsella
Ropes & Gray LLP
One International Place
Boston, Massachusetts 02110
Telephone: (617) 951-7000
CALCULATION OF FILING FEE
Transaction Valuation* |
Amount Of Filing Fee** |
|
$522,472,033 | $29,154 |
* | Estimated solely for purposes of calculating amount of filing fee in accordance with Rule 0-11 under the Securities Exchange Act of 1934. The transaction value is based upon the offer to purchase 18,016,277 outstanding shares of Common Stock of VNUS Medical Technologies, Inc. at a purchase price of $29.00 cash per share. Such number of outstanding shares of Common Stock represents the total of 16,234,156 issued and outstanding shares of Common Stock, outstanding options with respect to 1,063,784 shares of Common Stock and restricted stock units with respect to 718,337 shares of Common Stock, in each case as of May 13, 2009. |
** | The amount of filing fee is calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 5 for fiscal year 2009 issued by the Securities and Exchange Commission. Such fee equals .00558% of the transaction value. |
x | Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number or the Form or Schedule and the date of its filing. |
Amount Previously Paid: | $29,154 | |
Form or Registration No.: | Schedule TO-T | |
Filing Party: | Covidien Group S.a.r.l. | |
Date Filed: | May 18, 2009 |
¨ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which the statement relates:
x | third-party tender offer subject to Rule 14d-1. |
¨ | issuer tender offer subject to Rule 13e-4. |
¨ | going-private transaction subject to Rule 13e-3. |
¨ | amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender offer: ¨
This Amendment No. 2 to the Tender Offer Statement on Schedule TO (this Amendment ), filed with the Securities and Exchange Commission on June 2, 2009, amends and supplements the Tender Offer Statement on Schedule TO filed on May 18, 2009, as amended (the Schedule TO ), and relates to a tender offer by Covidien Delaware Corp., a Delaware corporation (the Offeror ) and a wholly owned subsidiary of Covidien Group S.a.r.l., a Luxembourg company ( Parent ), to purchase all of the outstanding shares of Common Stock, par value $0.001 per share (the Shares ), of VNUS Medical Technologies, Inc., a Delaware corporation (the Company ), at a purchase price of $29.00 per Share, net to the seller in cash, without interest thereon, less any applicable withholding taxes, and subject to the conditions set forth in the Offer to Purchase for Cash dated May 18, 2009 (the Offer to Purchase ) and in the related Letter of Transmittal (the Letter of Transmittal which, together with the Offer to Purchase, as each may be amended and supplemented from time to time, constitute the Offer ). This Amendment is being filed on behalf of the Offeror and Parent.
The information set forth in the Offer to Purchase and the Letter of Transmittal, copies of which are filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively, is incorporated by reference in answers to Items 1 through 9 and Item 11 of the Schedule TO, and is supplemented by the information specifically provided herein.
ITEM 11. | ADDITIONAL INFORMATION |
Item 11(a)(5) is hereby amended by replacing None. with the following paragraph:
On May 28, 2009, a purported stockholder of the Company filed a purported class action lawsuit in the Superior Court of the State of California, Santa Clara County, captioned Diegel Living Trust v. Brian Farley, et al., Case No. 109-CV-143338 (the Action ), against the Company, each of its directors, the Parent and the Offeror. The Action purports to be brought individually and on behalf of the public stockholders of the Company. The Action alleges that the Company director defendants breached their fiduciary duties to the Companys stockholders in connection with the Offer, that the Company, Parent and Offeror aided and abetted such alleged breach of the Company director defendants fiduciary duties and that the Company made inadequate disclosures in its Solicitation/Recommendation Statement on Schedule 14D-9 filed with the Securities and Exchange Commission on May 18, 2009, as subsequently amended and supplemented. Based on these allegations, the Action seeks, among other relief, injunctive relief preliminarily and permanently enjoining each of the Company, its directors, the Parent and the Offeror from consummating the Offer and the Merger. A copy of the complaint in the Action is included hereto as Exhibit (a)(5)(C) and is hereby incorporated herein by reference. The foregoing description is qualified in its entirety by reference to Exhibit (a)(5)(C).
ITEM 12. | EXHIBITS |
(a)(1)(A) | Offer to Purchase for Cash, dated May 18, 2009.* | |
(a)(1)(B) | Form of Letter of Transmittal.* | |
(a)(1)(C) | Form of Notice of Guaranteed Delivery.* | |
(a)(1)(D) | Form of Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees.* | |
(a)(1)(E) | Form of Letter to Clients for Use by Brokers, Dealers, Banks, Trust Companies and Other Nominees.* | |
(a)(2) | None. | |
(a)(3) | None. | |
(a)(4) | None. | |
(a)(5)(A) | Joint Press Release issued by Covidien Ltd. and VNUS Medical Technologies, Inc., dated May 8, 2009 (incorporated herein by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Covidien Ltd. on May 8, 2009).* | |
(a)(5)(B) | Summary Advertisement published in the Wall Street Journal on May 18, 2009.* | |
(a)(5)(C) | Complaint filed by Diegel Living Trust, individually and on behalf of all others similarly situated, on May 28, 2009, in the Superior Court of the State of California, Santa Clara County (incorporated herein by reference to Amendment No. 2 to the Solicitation/Recommendation Statement on Schedule 14D-9 filed by VNUS Medical Technologies, Inc. on June 1, 2009). | |
(b) | None. | |
(d)(1) | Agreement and Plan of Merger, dated as of May 7, 2009, by and between Covidien Group S.a.r.l., Covidien Delaware Corp. and VNUS Medical Technologies, Inc.* | |
(d)(2) | Form of Tender and Voting Agreement, dated as of May 7, 2009, by and between Covidien Group S.a.r.l., Covidien Delaware Corp. and certain stockholders of VNUS Medical Technologies, Inc. * | |
(d)(3) | Confidentiality and Standstill Agreement, dated as of February 3, 2009, by and between Tyco Healthcare Group LP and VNUS Medical Technologies, Inc.* | |
(d)(4) | Guaranty, dated as of May 7, 2009, by Covidien International Finance S.A.* | |
(g) | None. | |
(h) | None. |
* | Previously filed |
SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
COVIDIEN GROUP S.A.R.L. | ||||||||
Dated: June 2, 2009 | By: | / S / M ICHELANGELO F. S TEFANI | ||||||
Name: Title: |
Michelangelo F. Stefani General Manager |
COVIDIEN DELAWARE CORP. | ||||||||
Dated: June 2, 2009 | By: | / S / J OHN W. K APPLES | ||||||
Name: Title: |
John W. Kapples Vice President and Secretary |
EXHIBIT INDEX
(a)(1)(A) | Offer to Purchase for Cash, dated May 18, 2009.* | |
(a)(1)(B) | Form of Letter of Transmittal.* | |
(a)(1)(C) | Form of Notice of Guaranteed Delivery.* | |
(a)(1)(D) | Form of Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees.* | |
(a)(1)(E) | Form of Letter to Clients for Use by Brokers, Dealers, Banks, Trust Companies and Other Nominees.* | |
(a)(2) | None. | |
(a)(3) | None. | |
(a)(4) | None. | |
(a)(5)(A) | Joint Press Release issued by Covidien Ltd. and VNUS Medical Technologies, Inc., dated May 8, 2009 (incorporated herein by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Covidien Ltd. on May 8, 2009).* | |
(a)(5)(B) | Summary Advertisement published in the Wall Street Journal on May 18, 2009.* | |
(a)(5)(C) | Complaint filed by Diegel Living Trust, individually and on behalf of all others similarly situated, on May 28, 2009, in the Superior Court of the State of California, Santa Clara County (incorporated herein by reference to Amendment No. 2 to the Solicitation/Recommendation Statement on Schedule 14D-9 filed by VNUS Medical Technologies, Inc. on June 1, 2009). | |
(b) | None. | |
(d)(1) | Agreement and Plan of Merger, dated as of May 7, 2009, by and between Covidien Group S.a.r.l., Covidien Delaware Corp. and VNUS Medical Technologies, Inc.* | |
(d)(2) | Form of Tender and Voting Agreement, dated as of May 7, 2009, by and between Covidien Group S.a.r.l., Covidien Delaware Corp. and certain stockholders of VNUS Medical Technologies, Inc.* | |
(d)(3) | Confidentiality and Standstill Agreement, dated as of February 3, 2009, by and between Tyco Healthcare Group LP and VNUS Medical Technologies, Inc.* | |
(d)(4) | Guaranty, dated as of May 7, 2009, by Covidien International Finance S.A.* | |
(g) | None. | |
(h) | None. |
* | Previously Filed |
1 Year Vnus Medical Technologies (MM) Chart |
1 Month Vnus Medical Technologies (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions